48 results on '"Stübig, Thomas"'
Search Results
2. Marker für minimale Resterkrankung: Minimal Residual Disease
3. Immunopathology and Immunotherapy of Acute Lymphoblastic Leukemia
4. Immunopathology and Immunotherapy of Lymphoblastic Leukaemia
5. Dynamic of Bone Marrow Fibrosis Regression Predicts Survival after Allogeneic Stem Cell Transplantation for Myelofibrosis
6. CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies
7. Immune-Modulating Drugs and Hypomethylating Agents to Prevent or Treat Relapse after Allogeneic Stem Cell Transplantation
8. Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis
9. Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologous–Allogeneic Tandem Transplantation in Patients with Multiple Myeloma
10. Purification of CD4 + T Cells for Adoptive Immunotherapy after Allogeneic Hematopoietic Stem Cell Transplantation
11. Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation
12. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms
13. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
14. Comparative diagnostic performance of 18F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation
15. Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation
16. Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial
17. Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT)
18. Diagnostik lymphatischer Neoplasien
19. Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation: A Study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation
20. Allogeneic Stem Cell Transplantation for CML in Accelerate or Blastic Phase
21. 'C-Raf kontrollierte Signalwege zum Schutz der Tumorzelle vor Apoptose'
22. 5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity
23. Ruxolitinib As Pretreatment Before Allogeneic Stem Cell Transplantation For Myelofibrosis
24. Postallograft lenalidomide induces strong NK cell–mediated antimyeloma activity and risk for T cell–mediated GvHD: Results from a phase I/II dose-finding study
25. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
26. Effective Prevention of Acute and Chronic Graft-Versus-Host Disease with Anti-Lymphocyte Globulin (ATG) without Increase of Relapse in HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation.
27. Comparative diagnostic performance of 18F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation
28. Impact of the NK Cell Receptor LIR-1 (ILT-2/CD85j/LILRB1) on Cytotoxicity against Multiple Myeloma
29. Achievement of Sustained Molecular Remission Induces Long-Term Freedom From Disease After Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma
30. Donor Choice for Allogeneic Stem Cell Transplantation for AML – A Retrospective Single Centre Long-Term Analysis,
31. Lenalidomide Maintenance Therapy After Toxicity-Reduced Myeloablative Allograft As Salvage Therapy for Efractory/Relapsed Myeloma Patients
32. Purification of CD4+ T Cells for Adoptive Immunotherapy after Allogeneic Hematopoietic Stem Cell Transplantation
33. Introduction of Differential KIR Activation Mediated Patters of NK Cell Cytotoxicity Against Myeloma
34. Dose Finding Study of Lenalidomide as Maintenance Therapy In Multiple Myeloma After Allogeneic Stem Cell Transplantation
35. Donor KIR-Haplotype B Improved Relapse-Free Survival After Allogeneic Stem Cell Transplantation for Multiple Myeloma
36. Induction Chemotherapy Followed Immediately by Busulfan-Based Reduced Conditioning and Allografting in Elderly Patients with Advanced MDS or sAML.
37. Related Vs Unrelated Donors After Auto-Allo Tandem Stem Cell Transplantation for Newly Diagnosed Patients with Multiple Myeloma.
38. Osteoprotegerin expression in dendritic cells increases with maturation and is NF-κB-dependent
39. EZH2 Mutations Are Drivers of Clonal Hematopoiesis and Leukemic Transformation in a Mouse Model of Primary Myelofibrosis
40. C-Raf controlled pathways in the protection of tumor cells from apoptosis
41. The Pan- JAK Inhibitor Ruxolitinib Impairs T-Cell Activation, Cytokine Production and Proliferation In Vivo and In Vitro
42. Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation.
43. Comparative diagnostic performance of F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation.
44. Detection of a Stem Cell Population with Hemangioblastic Characteristics in Primary Myelofibrosis (PMF),
45. CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies.
46. Purification of CD4+ T Cells for Adoptive Immunotherapy after Allogeneic Hematopoietic Stem Cell Transplantation
47. CD133 marks a stem cell population that drives human primary myelofibrosis.
48. Osteoprotegerin expression in dendritic cells increases with maturation and is NF-kappaB-dependent.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.